Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR6 | P51684 | 1/20 | 0.49 |
| ▸ | HKDC1 | Q2TB90 | 1/20 | 0.49 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 5/20 | 0.46 |
| ▸ | CA1 | P00915 | 3/20 | 0.46 |
| ▸ | CA2 | P00918 | 3/20 | 0.46 |
| ▸ | CA12 | O43570 | 2/20 | 0.46 |
| ▸ | CA7 | P43166 | 2/20 | 0.46 |
| ▸ | CA9 | Q16790 | 2/20 | 0.46 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.46 |
| ▸ | XDH | P47989 | 1/20 | 0.46 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.43 |
| ▸ | CYP4A11 | Q02928 | 2/20 | 0.43 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 4/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.42 |
| ▸ | GLA | P06280 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27594634 | 0.87 | NOTUM (0.53) | CCR6HKDC1NOTUMMAPTCA1 | |
| SCHEMBL15903171 | 0.87 | NPC1 (0.56) | CCR6HKDC1NOTUMMAPTCA1 | |
| SCHEMBL3273922 | 0.87 | CCR6 (0.49) | CCR6HKDC1NOTUMMAPTCA1 | |
| SCHEMBL256770 | 0.87 | NOTUM (0.51) | CCR6HKDC1NOTUMMAPTCA1 | |
| SCHEMBL29715212 | 0.87 | NOTUM (0.51) | CCR6HKDC1NOTUMMAPTCA1 | |
| SCHEMBL17798915 | 0.86 | CCR6 (0.48) | CCR6HKDC1NOTUMMAPTCA1 | |
| SCHEMBL2358109 | 0.85 | NOTUM (0.53) | CCR6HKDC1NOTUMMAPTCA1 | |
| SCHEMBL27771420 | 0.84 | CA12 (0.51) | MAPTCA1CA2CA12CA7 | |
| SCHEMBL6617704 | 0.84 | MAPT (0.46) | CCR6HKDC1NOTUMMAPTCA1 | |
| SCHEMBL6618854 | 0.84 | ALDH1A1 (0.49) | CCR6HKDC1NOTUMMAPTCA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10183917-B2 | Tricyclic compounds and uses thereof in medicine | SUNSHINE LAKE PHARMA CO., LTD. (CN) | 2019-01-22 | — | — | US | disclosed |
| CN-102933563-A | Substituted 3,5-di phenyl-isoxazoline derivatives as insecticides and acaricides | AH US 42 CO LTD | 2013-02-13 | — | — | CN | disclosed |
| CN-102245602-A | Oxadiazole fused heterocyclic derivatives useful for the treatment of multiple sclerosis | MERCK SERONO SA | 2011-11-16 | — | — | CN | disclosed |
| CN-101970420-A | Oxadiazole derivatives | MERCK SERONO SA | 2011-02-09 | — | — | CN | disclosed |
| CN-101910121-A | Bis (sulfonylamino) derivatives 066 in therapy | ASTRAZENECA AB | 2010-12-08 | — | — | CN | disclosed |
| CN-101815707-A | oxadiazole diaryl compounds | MERCK SERONO SA | 2010-08-25 | — | — | CN | disclosed |
| CN-1149196-C | Biphenyl sulfonamides as dual angiotensin endothelin receptor antagonists | ����˹�ж�-����˹˹������˾ | 2004-05-12 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10183917-B2 | Tricyclic compounds and uses thereof in medicine | NR1H4, SLC10A1, SLC10A2 | CCR6 1099/4885HKDC1 1720/4885NOTUM 1258/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.